Eudald Felip1,2,3, Laia Llobera2, Clara Perez-Mañá4,5, David Quintela6, Ignacio Guasch7, Mireia Margelí1,2, Iris Teruel1,2, Beatriz Cirauqui1,2, Carmen Centeno8, Margarita Romeo1,2, Ester Ballana3, Vanesa Quiroga1. 1. Badalona Applied Research Group in Oncology (B-ARGO Group), Oncology Department, Catalan Institute of Oncology, Badalona, Spain. 2. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. 3. AIDS Research Institute-IrsiCaixa and Health Research Institute Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Spain. 4. Clinical Pharmacology Unit, Hospital Germans Trias i Pujol, Badalona, Spain, Badalona, Spain. 5. Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Cerdanyola del Vallès, Spain. 6. Department of Clinical Hematology, Catalan Intistute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain. 7. Radiology Department, Hospital Germans Trias i Pujol, Badalona, Spain. 8. Pulmonology Department, Hospital Germans Trias i Pujol, Badalona, Spain.
Abstract
BACKGROUND: Palbociclib is a specific inhibitor of cyclin-dependent kinases 4 and 6 that is approved for the treatment of advanced or metastatic breast cancer patients. Despite a good toxicity profile in pivotal trials, where asymptomatic neutropenia was the main adverse effect, its wider use in clinical practice may show less prevalent but serious toxicities. CASE PRESENTATION: Here, we describe a case of pneumonitis due to palbocicblib. A 57-year-old female with breast cancer with bone metastasis presented dyspnea at rest 3 months after beginning treatment with palbociclib and letrozole. Palbociclib-induced pneumonitis was considered the most probable cause after ruling out all alternatives, and the patient was successfully treated with steroids and showed complete remission. CONCLUSIONS: In summary, we present a well-documented case report of pneumonitis related to palbociclib. However, the mechanism of toxicity is still unknown, and there are as yet no reliable biomarkers to predict toxicity with cyclin-dependent kinase 4/6 inhibitors. In this case report, we alert physicians about new drugs that can provoke old toxicities.
BACKGROUND: Palbociclib is a specific inhibitor of cyclin-dependent kinases 4 and 6 that is approved for the treatment of advanced or metastatic breast cancer patients. Despite a good toxicity profile in pivotal trials, where asymptomatic neutropenia was the main adverse effect, its wider use in clinical practice may show less prevalent but serious toxicities. CASE PRESENTATION: Here, we describe a case of pneumonitis due to palbocicblib. A 57-year-old female with breast cancer with bone metastasis presented dyspnea at rest 3 months after beginning treatment with palbociclib and letrozole. Palbociclib-induced pneumonitis was considered the most probable cause after ruling out all alternatives, and the patient was successfully treated with steroids and showed complete remission. CONCLUSIONS: In summary, we present a well-documented case report of pneumonitis related to palbociclib. However, the mechanism of toxicity is still unknown, and there are as yet no reliable biomarkers to predict toxicity with cyclin-dependent kinase 4/6 inhibitors. In this case report, we alert physicians about new drugs that can provoke old toxicities.
Authors: Maura N Dickler; Sara M Tolaney; Hope S Rugo; Javier Cortés; Véronique Diéras; Debra Patt; Hans Wildiers; Clifford A Hudis; Joyce O'Shaughnessy; Esther Zamora; Denise A Yardley; Martin Frenzel; Andrew Koustenis; José Baselga Journal: Clin Cancer Res Date: 2017-05-22 Impact factor: 12.531
Authors: C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt Journal: Clin Pharmacol Ther Date: 1981-08 Impact factor: 6.875
Authors: Jun Gong; May Cho; Kim Wai Yu; James Waisman; Yuan Yuan; Joanne Mortimer Journal: Breast Cancer Res Treat Date: 2017-12-07 Impact factor: 4.872